Sell2Wales.gov.wales uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies.

Accept cookies Cookie Settings

View Notice

The buyer is not using this website to administer the notice. To record your interest or obtain additional information or documents please find instructions within the Full Notice Text. (NOTE: Contract Award Notices and Prior Information Notices do not normally require a response)

Add notice to my Sell2Wales Interest List

Notice Details

Title: Procurement of National Influenza Vaccine Stock for 2020/21 Flu Season
Published by: Department of Health and Social Care
Publication Date: 27/11/2020
Deadline Date:
Deadline Time:
Notice Type: Contract Award Notice
Has Documents: No
Has ESPD: No
Abstract:

Direct Award using Regulation 32 of PCR 2015.

Contract award notice

Results of the procurement procedure

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting entity

I.1) Name and addresses

Department of Health and Social Care

39 Victoria Street

London

SW1H 0EU

UK

E-mail: simeon.hadebe@dhsc.gov.uk

NUTS: UKI32

Internet address(es)

Main address: https://www.gov.uk/government/organisations/department-of-health-and-social-care

Address of the buyer profile: https://www.gov.uk/government/organisations/department-of-health-and-social-care

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Procurement of National Influenza Vaccine Stock for 2020/21 Flu Season

Reference number: Project Number:1126 Contract Number:11961

II.1.2) Main CPV code

33651660

 

II.1.3) Type of contract

Supplies

II.1.4) Short description

This contract is for the supply of a central national stock of influenza vaccine.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement

Value excluding VAT: 47 000 000.00 GBP

II.2) Description

II.2.3) Place of performance

NUTS code:

UKD7

II.2.4) Description of the procurement

Direct Award using Regulation 32 of PCR 2015.

II.2.5) Award criteria

Quality criterion: Suitability of the products / Weighting: First

Quality criterion: Availability of the contractor's products / Weighting: Second

Cost criterion: Cost of the contractor's products / Weighting: Third

II.2.11) Information about options

Options: No

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the Official Journal of the European Union

Justification for selected award procedure:

Extreme urgency brought about by events unforeseeable for the contracting authority and in accordance with the strict conditions stated in the Directive

Explanation

Justification for the choice of the negotiated procedure without prior publication of a call for competition in accordance with Article 32 of Directive 2014/24/EU: extreme urgency brought about by events unforeseeable for the contracting authority and in accordance with the strict conditions stated in the directive.

Explanation:

1) The coronavirus disease (Covid-19) is a serious infectious respiratory disease and its consequences pose a risk to life. The WHO Director General characterised Covid-19 as a pandemic on 11 March 2020, by this stage Europe was the centre of the pandemic.

2) Influenza vaccination gives higher risk groups direct protection, and decreases the prevalence of influenza in the community thereby protecting lower risk groups and those who cannot get vaccinated. This procurement is for an urgent national buffer stock of vaccines which will be used to substantially expand the usual numbers vaccinated in light of the risk presented by Covid-19.

3) Due to the additional risks of flu and Covid-19 co-circulating, the authority wishes to expand cohorts to cover year 7 children, household contacts of those on the Covid-19 shielding list, and over 50s, and increase uptake in all existing cohorts. This strategy will reduce the numbers of co-infections of Covid-19 and flu, which if they were to occur, will:

— place exceptional pressures on the National Health Service and care services;

— potentially increase the severity of the diseases in individuals;

— potentially lead to misclassification because of overlapping clinical syndromes and the currently imperfect detection of viral pathogen in respiratory samples; and

— potentially makes transmission of both diseases more likely.

4) These concerns have led to a global race for additional flu vaccines. The global stock of these vaccines is limited and there are many buyers competing for the same supplies. It is imperative that security of supply is maintained for public health purposes. In these circumstances, a procurement following the usual timescales under the PCR 2015, including accelerated options, was not feasible.

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V: Award of contract

A contract/lot is awarded: Yes

V.2 Award of contract

V.2.1) Date of conclusion of the contract

15/06/2020

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor

Aventis Pharma ltd t/a Sanofi

01535640

410, Thames Valley Park Drive

Reading

RG6 1PT

UK

NUTS: UKJ1

The contractor is an SME: No

V.2.4) Information on value of the contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: 47 000 000.00 GBP

Total value of the contract/lot: 47 000 000.00 GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information

Extreme urgency brought about by events unforeseeable for the contracting authority and in accordance with the strict conditions stated in the directive.

VI.4) Procedures for review

VI.4.1) Review body

The High Court

Strand

London

WC2A 2LL

UK

Internet address(es)

URL: https://www.gov.uk/courts-tribunals

VI.4.3) Review procedure

Precise information on deadline(s) for review procedures:

Review procedures are set out in the Public Contracts Regulations 2015. Proceedings under the Public Contracts Regulations 2015 are time limited and any such proceedings must be brought in the High Court of England and Wales.

VI.5) Date of dispatch of this notice

22/11/2020


Information added to the notice since publication.

Additional information added to the notice since it's publication.
No further information has been uploaded.
Main Contact: simeon.hadebe@dhsc.gov.uk
Admin Contact: N/a
Technical Contact: N/a
Other Contact: N/a

Commodity Categories

Commodity Categories
IDTitleParent Category
33651660Influenza vaccinesGeneral anti-infectives for systemic use and vaccines

Delivery Locations

Delivery Locations
IDDescription
100UK - All

Alert Region Restrictions

The buyer has restricted the alert for this notice to suppliers based in the following regions.

Alert Region Restrictions
There are no alert restrictions for this notice.

Copyright © Sell2Wales